Vaccination with the extracellular domain of p185 neu prevents mammary tumor development in neu transgenic mice

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

Tolerance, Danger, and the Extended Family

1994 • 4,654 citations

T cell tolerance by clonal elimination in the thymus

1987 • 2,248 citations

Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes

1988 • 1,711 citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

1992 • 1,190 citations

Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice

1991 • 1,187 citations

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

1988 • 1,160 citations

T-cell apoptosis detected in situ during positive and negative selection in the thymus

1994 • 1,071 citations

T-cell receptor Vβ use predicts reactivity and tolerance to Mlsa- encoded antigens

1988 • 901 citations

Neu-Protein Overexpression in Breast Cancer

1988 • 860 citations

Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response

1991 • 766 citations

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

1990 • 763 citations

Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity

1993 • 688 citations

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

1990 • 640 citations

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

1995 • 542 citations

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

1994 • 467 citations

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

1995 • 446 citations

p185neu expression in human lung adenocarcinomas predicts shortened survival.

1990 • 440 citations

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1985 • 408 citations

Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.

1991 • 331 citations

How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model

1994 • 309 citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1996 • 308 citations

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1991 • 296 citations

Is cancer dangerous to the immune system?

1996 • 296 citations

Transgenic Models of Tumor Development

1991 • 289 citations

Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue.

1988 • 251 citations

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease

1991 • 250 citations

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.

1986 • 231 citations

Peripheral T Cell Tolerance

1992 • 223 citations

The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.

1992 • 196 citations

Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice.

1994 • 194 citations

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1996 • 185 citations

Immunity to Oncogenic Proteins

1995 • 180 citations

HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.

1994 • 174 citations

Stability of HER-2/neu Expression Over Time and at Multiple Metastatic Sites

1993 • 161 citations

Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.

1986 • 158 citations

Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.

1997 • 157 citations

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

1995 • 149 citations

Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas.

1989 • 130 citations

Amplification and expression of the c‐erb B‐2/neu proto‐oncogene in human bladder cancer

1990 • 111 citations

Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.

1993 • 105 citations

Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines

1992 • 101 citations

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.

1987 • 98 citations

Transgenic mouse models of mammary tumorigenesis.

1993 • 83 citations

Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene.

1995 • 78 citations

Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.

1990 • 63 citations

Dose‐dependent T cell tolerance to an immunodominant self peptide

1994 • 57 citations

Escape of Thymocytes and Mature T Cells from Clonal Deletion Due to Limiting Tolerogen Expression Levels

1994 • 57 citations

Mammalian cell transient expression of tissue factor for the production of antigen

1990 • 50 citations

The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.

1990 • 45 citations

Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro

1994 • 42 citations

A peripheral mechanism preserves self-tolerance to a secreted protein in transgenic mice.

1990 • 41 citations

Hen egg-white lysozyme-specific T cells elicited in hen egg-white lysozyme-transgenic mice retain an imprint of self-tolerance.

1993 • 35 citations

T‐cell recognition of oncogene products: A new strategy for immunotherapy

1992 • 27 citations

Comparison of the T cell receptors on insulin-specific hybridomas from insulin transgenic and nontransgenic mice. Loss of a subpopulation of self-reactive clones.

1992 • 15 citations